Medigene Management
Management criteria checks 4/4
Medigene's CEO is Selwyn Ho, appointed in Jul 2022, has a tenure of 2.42 years. total yearly compensation is €445.00K, comprised of 80.9% salary and 19.1% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth €63.34K. The average tenure of the management team and the board of directors is 2.1 years and 7.3 years respectively.
Key information
Selwyn Ho
Chief executive officer
€445.0k
Total compensation
| CEO salary percentage | 80.9% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.1yrs |
| Board average tenure | 7.3yrs |
Recent management updates
This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO
Jun 17
How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?
Dec 23Recent updates
Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation
Jan 03The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business
Aug 12Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%
Aug 10We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely
Mar 24Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation
Nov 29This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO
Jun 17We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate
Mar 29How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 16How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?
Dec 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€16m |
| Mar 31 2024 | n/a | n/a | -€16m |
| Dec 31 2023 | €445k | €360k | -€16m |
| Sep 30 2023 | n/a | n/a | -€23m |
| Jun 30 2023 | n/a | n/a | -€29m |
| Mar 31 2023 | n/a | n/a | -€19m |
| Dec 31 2022 | €612k | €157k | -€8m |
Compensation vs Market: Selwyn's total compensation ($USD464.32K) is about average for companies of similar size in the German market ($USD469.36K).
Compensation vs Earnings: Selwyn's compensation has been consistent with company performance over the past year.
CEO
Selwyn Ho (53 yo)
2.4yrs
Tenure
€445,000
Compensation
Dr. Selwyn Ho, MBBS, serves as Chief Executive Officer & Chairman of the Executive Management Board at Medigene AG since July 25, 2022. He served as Chief Business Officer at Connect Biopharma Holdings Lim...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of Executive Management Board | 2.4yrs | €445.00k | 0.42% € 63.3k | |
| Chief Scientific Officer | 10.6yrs | €486.00k | no data | |
| Co-Founder & Chairman Scientific Advisory Board | no data | €20.00k | no data | |
| Chief Financial Officer | no data | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | 1.8yrs | no data | no data | |
| VP and Head of Clinical Research & Development | 1.8yrs | no data | no data |
2.1yrs
Average Tenure
Experienced Management: MDG1's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman Scientific Advisory Board | 7.3yrs | €20.00k | no data | |
| Independent Member of the Supervisory Board | 4yrs | €24.00k | no data | |
| Independent Deputy Chairwomen of the Supervisory Board | 8.3yrs | €38.00k | no data | |
| Independent Chairman of the Supervisory Board | 7.6yrs | €45.00k | no data | |
| Independent Member of the Supervisory Board | 7.6yrs | €26.00k | no data | |
| Independent Member of the Supervisory Board | 6.6yrs | €30.00k | 0.071% € 10.8k | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data |
7.3yrs
Average Tenure
68yo
Average Age
Experienced Board: MDG1's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medigene AG is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xian Deng | Berenberg |
| Gary Waanders | Bryan Garnier & Co |
| Thibaud Rutsaert | GSN North America |